Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 1, 2016

View Archived Issues

EIB and Transgene enter a financing agreement

Adicet Bio closes Series A financing and acquires Applied Immune Technologies

Epic Sciences and Avera Medical collaborate in personalized cancer medicine trials

RSV Corporation ends RSV collaboration with Mymetics

Shionogi and Nissan Chemical enter strategic antifungal research collaboration agreement

Elotuzumab receives positive CHMP opinion for the treatment of multiple myeloma

VARI-SU2C Epigenetics Dream Team advances trial for metastatic colorectal cancer

Synthetic anion carrier shows activity without toxicity

AbbVie starts enrollment in phase III clinical program for elagolix in uterine fibroids

First patients dosed in phase I trial of ARQ-092 in Proteus syndrome

GenArraytion introduces first commercially available Zika virus test

Cancer drug exhibits promising preclinical results in a DMD model

Allergan enters into a global agreement with AstraZeneca to develop and commercialize ATM-AVI

Celgene reviews activities of fourth quarter 2015

Sareum applies for permission to start clinical trials of Chk1 inhibitor CCT-245737

Amgen reports milestones from fourth quarter 2015

EMA accepts cabozantinib MAA for review

BeiGene reports inhibitors of EGFR T790M mutant

Synergy Pharmaceuticals submits NDA for plecanatide

Pfizer reports muscarinic M1 PAMs

Merck Patent and Cancer Research Technology develop CDK8/19 inhibitors

EMA committee backs approval of Uptravi for PAH

Advenchen Laboratories presents PI3K/mTOR inhibitors

EMA committee recommends approval of Coagadex to treat FX deficiency

FDA gives breakthrough therapy designation to Allergan's rapastinel

Merck & Co. reports ROMK inhibitors

Spectrum Pharmaceuticals begins registrational trial of eflapegrastim

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...